Cost-effectiveness of a telemonitoring program (telEPOC program) in frequently admitted chronic obstructive pulmonary disease patients

被引:5
|
作者
Esteban, Cristobal [1 ,2 ,3 ]
Anton, Ane [2 ,4 ,5 ]
Moraza, Javier [1 ,3 ]
Iriberri, Milagros [3 ,6 ]
Larrauri, Mateo [3 ,7 ]
Mar, Javier [2 ,8 ,9 ]
Aramburu, Amaia [1 ,3 ]
Quintana, Jose M. [2 ,3 ,4 ]
机构
[1] Hosp Galdakao, Serv Neumol, Galdakao, Spain
[2] Red Invest Serv Sanitarios & Enfermedades Cronica, Barcelona, Spain
[3] BioCrues Bizkaia Hlth Res Inst, Baracaldo, Spain
[4] Hosp Galdakao, Unidad Invest, Galdakao, Spain
[5] Kronikgune Res Inst, Baracaldo, Spain
[6] Hosp Cruces, Serv Neumol, Baracaldo, Spain
[7] Organ Sanitaria Integrada Barrualde, Atenc Primaria, Galdakao, Spain
[8] OSI Alto Deba, Clin Management Unit, Alto Deba, Spain
[9] Biodonostia Hlth Res Inst, Donostia San Sebastian, Spain
关键词
Chronic obstructive pulmonary disease; telemonitoring; cost-effectiveness; telehealth; HEALTH; CARE;
D O I
10.1177/1357633X211037207
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Chronic obstructive pulmonary disease is a typical disease among chronic and respiratory diseases. The costs associated with chronic disease care are rising dramatically, and this makes it necessary to redesign care processes, including new tools which allow the health system to be more sustainable without compromising on the quality of the care, compared to that currently provided. One approach may be to use information and communication technologies. In this context, we explored the cost-effectiveness of applying a telemonitoring system to a cohort of chronic obstructive pulmonary disease patients with frequent readmissions (the telEPOC programme). We conducted an intervention study with a control group. The inclusion criteria used were having chronic obstructive pulmonary disease (forced expiratory volume in the first second/forced vital capacity < 70%) and having been hospitalised for exacerbation at least twice in the last year or three times in the last 2 years. We estimated the costs incurred by patients in each group and calculated the quality-adjusted life years and incremental cost-effectiveness ratio. Overall, 77 patients were included in the control group and 86 in the intervention group. The raw cost-effectiveness analysis showed that the cost of the telEPOC intervention was significantly lower than that of usual care, while there were no significant differences between the groups in effectiveness. The incremental cost-effectiveness ratio for the intervention was euro175,719.71 per quality-adjusted life-year gained. There were no differences between the intervention group (telemonitoring) and the control group (standard care) from the cost-effectiveness point of view. On the other hand, the intervention programme (telEPOC) was less expensive than routine clinical practice.
引用
收藏
页码:156 / 164
页数:9
相关论文
共 50 条
  • [31] Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting
    Andrew D. Scarffe
    Christopher J. Licskai
    Madonna Ferrone
    Kevin Brand
    Kednapa Thavorn
    Doug Coyle
    Cost Effectiveness and Resource Allocation, 20
  • [32] Cost-effectiveness of chronic obstructive pulmonary disease population screening in China: based on individual data from WHO Collaborating Centre-initiated ‘Enjoying Breathing Program’
    Tiantian Zhang
    Jiahuan Ai
    Ke Huang
    Peiyao Lu
    Xiao Tang
    Jieping Lei
    Xue Li
    Esther W. Chan
    Qiming Wen
    Xiaoqin Wen
    Fang Fang
    Cunbo Jia
    Ian C. K. Wong
    Jie Jiang
    Ting Yang
    Chen Wang
    BMC Public Health, 25 (1)
  • [33] Effectiveness of Telemonitoring in Patients with Chronic Obstructive Pulmonary Disease in Taiwan-A Randomized Controlled Trial
    Ho, Te-Wei
    Huang, Chun-Ta
    Chiu, Herng-Chia
    Ruan, Sheng-Yuan
    Tsai, Yi-Ju
    Yu, Chong-Jen
    Lai, Feipei
    SCIENTIFIC REPORTS, 2016, 6
  • [34] One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
    Oostenbrink, JB
    Rutten-van Mölken, MPMH
    Al, MJ
    Van Noord, JA
    Vincken, W
    EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (02) : 241 - 249
  • [35] A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease
    Kirsch, Florian
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (02) : 301 - 316
  • [36] The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator
    Mattias Neyt
    Ann Van Den Bruel
    The European Journal of Health Economics, 2012, 13 : 379 - 380
  • [37] Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting
    Scarffe, Andrew D.
    Licskai, Christopher J.
    Ferrone, Madonna
    Brand, Kevin
    Thavorn, Kednapa
    Coyle, Doug
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
  • [38] Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data
    Briggs, Andrew H.
    Lozano-Ortega, Greta
    Spencer, Sally
    Bale, Geraldine
    Spencer, Michael D.
    Burge, P. Sherwood
    VALUE IN HEALTH, 2006, 9 (04) : 227 - 235
  • [39] Psychological outcomes of an outpatient pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease
    Kayahan, Bulent
    Karapolat, Hale
    Atyntoprak, Ender
    Atasever, Alev
    Ozturk, Ozgur
    RESPIRATORY MEDICINE, 2006, 100 (06) : 1050 - 1057
  • [40] A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand
    Prasitwarachot, Ratthanon
    Thavorn, Kednapa
    Patikorn, Chanthawat
    Wattanasirichaigoon, Somkiat
    Rungruanghiranya, Suthat
    Thongphiew, Araya
    Chaiyakunapruk, Nathorn
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1377 - 1385